These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 37470295)
1. Prediction of relative change in free nerve growth factor following subcutaneous administration of tanezumab, a novel monoclonal antibody to nerve growth factor. Shoji S; Suzuki A; Nouri P; Cai CH; Gaitonde P; Marshall S CPT Pharmacometrics Syst Pharmacol; 2023 Sep; 12(9):1358-1370. PubMed ID: 37470295 [TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics of tanezumab following intravenous or subcutaneous administration to patients with osteoarthritis or chronic low back pain. Shoji S; Suzuki A; Gaitonde P; Cai CH; Marshall S Br J Clin Pharmacol; 2022 Jul; 88(7):3321-3334. PubMed ID: 35112378 [TBL] [Abstract][Full Text] [Related]
3. Tanezumab for the treatment of osteoarthritis pain. Gondal FR; Bilal J; Kent Kwoh C Drugs Today (Barc); 2022 Apr; 58(4):187-200. PubMed ID: 35412532 [TBL] [Abstract][Full Text] [Related]
4. Peripheral Nerve Safety of Nerve Growth Factor Inhibition by Tanezumab: Pooled Analyses of Phase III Clinical Studies in Over 5000 Patients with Osteoarthritis. Brown MT; Cornblath DR; Koltzenburg M; Gorson KC; Hickman A; Pixton GC; Gaitonde P; Viktrup L; West CR Clin Drug Investig; 2023 Jul; 43(7):551-563. PubMed ID: 37460782 [TBL] [Abstract][Full Text] [Related]
5. From the Cover: Evaluation of the Effects of Tanezumab, a Monoclonal Antibody Against Nerve Growth Factor, on the Sympathetic Nervous System in Adult Cynomolgus Monkeys (Macaca fascicularis): A Stereologic, Histomorphologic, and Cardiofunctional Assessment. Belanger P; Butler P; Butt M; Bhatt S; Foote S; Shelton D; Evans M; Arends R; Hurst S; Okerberg C; Cummings T; Potter D; Steidl-Nichols J; Zorbas M Toxicol Sci; 2017 Aug; 158(2):319-333. PubMed ID: 28525647 [TBL] [Abstract][Full Text] [Related]
6. Probing the binding mechanism and affinity of tanezumab, a recombinant humanized anti-NGF monoclonal antibody, using a repertoire of biosensors. Abdiche YN; Malashock DS; Pons J Protein Sci; 2008 Aug; 17(8):1326-35. PubMed ID: 18505735 [TBL] [Abstract][Full Text] [Related]
7. Characterization of adverse joint outcomes in patients with osteoarthritis treated with subcutaneous tanezumab. Carrino JA; McAlindon TE; Schnitzer TJ; Guermazi A; Hochberg MC; Conaghan PG; Brown MT; Burr A; Fountaine RJ; Pixton GC; Viktrup L; Verburg KM; West CR Osteoarthritis Cartilage; 2023 Dec; 31(12):1612-1626. PubMed ID: 37652258 [TBL] [Abstract][Full Text] [Related]
8. Anti-nerve growth factor in the treatment of low back pain and radiculopathy: a systematic review and a meta-analysis. Leite VF; Buehler AM; El Abd O; Benyamin RM; Pimentel DC; Chen J; Hsing WT; Mazloomdoost D; Amadera JE Pain Physician; 2014; 17(1):E45-60. PubMed ID: 24452657 [TBL] [Abstract][Full Text] [Related]
9. Effects of Monoclonal Antibodies against Nerve Growth Factor on Healthy Bone and Joint Tissues in Mice, Rats, and Monkeys: Histopathologic, Biomarker, and Microcomputed Tomographic Assessments. Gropp KE; Carlson CS; Evans MG; Bagi CM; Reagan WJ; Hurst SI; Shelton DL; Zorbas MA Toxicol Pathol; 2018 Jun; 46(4):408-420. PubMed ID: 29768985 [TBL] [Abstract][Full Text] [Related]
10. Effect of Tanezumab on Joint Pain, Physical Function, and Patient Global Assessment of Osteoarthritis Among Patients With Osteoarthritis of the Hip or Knee: A Randomized Clinical Trial. Schnitzer TJ; Easton R; Pang S; Levinson DJ; Pixton G; Viktrup L; Davignon I; Brown MT; West CR; Verburg KM JAMA; 2019 Jul; 322(1):37-48. PubMed ID: 31265100 [TBL] [Abstract][Full Text] [Related]
11. Impact of tanezumab on health status, non-work activities and work productivity in adults with moderate-to-severe osteoarthritis. Conaghan PG; Abraham L; Viktrup L; Cislo P BMC Musculoskelet Disord; 2022 Feb; 23(1):106. PubMed ID: 35105318 [TBL] [Abstract][Full Text] [Related]
12. Long-Term Safety and Efficacy of Subcutaneous Tanezumab Versus Nonsteroidal Antiinflammatory Drugs for Hip or Knee Osteoarthritis: A Randomized Trial. Hochberg MC; Carrino JA; Schnitzer TJ; Guermazi A; Walsh DA; White A; Nakajo S; Fountaine RJ; Hickman A; Pixton G; Viktrup L; Brown MT; West CR; Verburg KM Arthritis Rheumatol; 2021 Jul; 73(7):1167-1177. PubMed ID: 33538113 [TBL] [Abstract][Full Text] [Related]
13. Observed efficacy and clinically important improvements in participants with osteoarthritis treated with subcutaneous tanezumab: results from a 56-week randomized NSAID-controlled study. Neogi T; Hunter DJ; Churchill M; Shirinsky I; White A; Guermazi A; Omata M; Fountaine RJ; Pixton G; Viktrup L; Brown MT; West CR; Verburg KM Arthritis Res Ther; 2022 Mar; 24(1):78. PubMed ID: 35351194 [TBL] [Abstract][Full Text] [Related]
14. Neurological safety of subcutaneous tanezumab versus NSAID in patients with osteoarthritis. Brown MT; Sandroni P; Low PA; Gorson KC; Hunter DJ; Pixton GC; Fountaine RJ; Viktrup L; West CR; Verburg KM J Neurol Sci; 2022 Mar; 434():120184. PubMed ID: 35217440 [TBL] [Abstract][Full Text] [Related]
15. Tanezumab in the treatment of chronic musculoskeletal conditions. Jayabalan P; Schnitzer TJ Expert Opin Biol Ther; 2017 Feb; 17(2):245-254. PubMed ID: 27936977 [TBL] [Abstract][Full Text] [Related]
16. Efficacy, General Safety, and Joint Safety of Tanezumab in Japanese Patients with Osteoarthritis: Subgroup Analyses from Two Randomized, Phase 3 Studies. Miki K; Ohta M; Abe M; Yoshimatsu H; Fujii K; Ebata N; West CR; Brown MT; Pixton G; Isogawa N Pain Ther; 2022 Sep; 11(3):827-844. PubMed ID: 35538185 [TBL] [Abstract][Full Text] [Related]
17. Nerve growth factor inhibition with tanezumab influences weight-bearing and subsequent cartilage damage in the rat medial meniscal tear model. LaBranche TP; Bendele AM; Omura BC; Gropp KE; Hurst SI; Bagi CM; Cummings TR; Grantham LE; Shelton DL; Zorbas MA Ann Rheum Dis; 2017 Jan; 76(1):295-302. PubMed ID: 27381034 [TBL] [Abstract][Full Text] [Related]
18. A multiple-dose toxicity study of tanezumab in cynomolgus monkeys. Zorbas M; Hurst S; Shelton D; Evans M; Finco D; Butt M Regul Toxicol Pharmacol; 2011 Mar; 59(2):334-42. PubMed ID: 21130822 [TBL] [Abstract][Full Text] [Related]
19. Nerve safety of tanezumab, a nerve growth factor inhibitor for pain treatment. Brown MT; Herrmann DN; Goldstein M; Burr AM; Smith MD; West CR; Verburg KM; Dyck PJ J Neurol Sci; 2014 Oct; 345(1-2):139-47. PubMed ID: 25073573 [TBL] [Abstract][Full Text] [Related]
20. Gender, age, disease severity, body mass index and diabetes may not affect response to subcutaneous tanezumab in patients with osteoarthritis after 16 weeks of treatment. A subgroup analysis of placebo-controlled trials. Berenbaum F; Schnitzer T; Kivitz A; Viktrup L; Johnston E; Yang R; Whalen E; Tive L; Semel D Int J Clin Pract; 2021 Dec; 75(12):e14975. PubMed ID: 34626502 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]